Importance of target-mediated drug disposition for small molecules
•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches. Target concentration is typically not cons...
Gespeichert in:
Veröffentlicht in: | Drug discovery today 2018-12, Vol.23 (12), p.2023-2030 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2030 |
---|---|
container_issue | 12 |
container_start_page | 2023 |
container_title | Drug discovery today |
container_volume | 23 |
creator | Smith, Dennis A. van Waterschoot, Robert A.B. Parrott, Neil J. Olivares-Morales, Andrés Lavé, Thierry Rowland, Malcolm |
description | •Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches.
Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development. |
doi_str_mv | 10.1016/j.drudis.2018.06.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2058499901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644618300837</els_id><sourcerecordid>2058499901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwDxDKyJJgO3FiL0hQ8VGpEgvMlmNfKldJXWwHiX-PqxRGprvhfe_RPQhdE1wQTOq7bWH8aGwoKCa8wHWBCT5Bc8IbnjNe0tO0l0zkdVXVM3QRwhZjQgWrz9GMCkE5Z3iOHlfD3vmodhoy12VR-Q3EfABjVQSTJcQmS5C9CzZat8s657MwqL7PBteDHnsIl-isU32Aq-NcoI_np_fla75-e1ktH9a5Lmsac0W4bo0yLUBT1STt2uhGEC6g0gyXmrdEMyIaWjJotCpNixuBO0W54V2rywW6ne7uvfscIUQ52KCh79UO3BgkxYxXQghMUrSaotq7EDx0cu_toPy3JFge7MmtnOzJgz2Ja5nspdrNkTC2ScFf6VdXCtxPAUh_flnwMmgLyZ2xHnSUxtn_CT_X_YQJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2058499901</pqid></control><display><type>article</type><title>Importance of target-mediated drug disposition for small molecules</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</creator><creatorcontrib>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</creatorcontrib><description>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches.
Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2018.06.010</identifier><identifier>PMID: 29928850</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Clinical Trials as Topic ; Drug Delivery Systems - methods ; Humans ; Small Molecule Libraries - pharmacokinetics ; Tissue Distribution - physiology</subject><ispartof>Drug discovery today, 2018-12, Vol.23 (12), p.2023-2030</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</citedby><cites>FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</cites><orcidid>0000-0001-9959-0810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1359644618300837$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29928850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Dennis A.</creatorcontrib><creatorcontrib>van Waterschoot, Robert A.B.</creatorcontrib><creatorcontrib>Parrott, Neil J.</creatorcontrib><creatorcontrib>Olivares-Morales, Andrés</creatorcontrib><creatorcontrib>Lavé, Thierry</creatorcontrib><creatorcontrib>Rowland, Malcolm</creatorcontrib><title>Importance of target-mediated drug disposition for small molecules</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches.
Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</description><subject>Animals</subject><subject>Clinical Trials as Topic</subject><subject>Drug Delivery Systems - methods</subject><subject>Humans</subject><subject>Small Molecule Libraries - pharmacokinetics</subject><subject>Tissue Distribution - physiology</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwDxDKyJJgO3FiL0hQ8VGpEgvMlmNfKldJXWwHiX-PqxRGprvhfe_RPQhdE1wQTOq7bWH8aGwoKCa8wHWBCT5Bc8IbnjNe0tO0l0zkdVXVM3QRwhZjQgWrz9GMCkE5Z3iOHlfD3vmodhoy12VR-Q3EfABjVQSTJcQmS5C9CzZat8s657MwqL7PBteDHnsIl-isU32Aq-NcoI_np_fla75-e1ktH9a5Lmsac0W4bo0yLUBT1STt2uhGEC6g0gyXmrdEMyIaWjJotCpNixuBO0W54V2rywW6ne7uvfscIUQ52KCh79UO3BgkxYxXQghMUrSaotq7EDx0cu_toPy3JFge7MmtnOzJgz2Ja5nspdrNkTC2ScFf6VdXCtxPAUh_flnwMmgLyZ2xHnSUxtn_CT_X_YQJ</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Smith, Dennis A.</creator><creator>van Waterschoot, Robert A.B.</creator><creator>Parrott, Neil J.</creator><creator>Olivares-Morales, Andrés</creator><creator>Lavé, Thierry</creator><creator>Rowland, Malcolm</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9959-0810</orcidid></search><sort><creationdate>201812</creationdate><title>Importance of target-mediated drug disposition for small molecules</title><author>Smith, Dennis A. ; van Waterschoot, Robert A.B. ; Parrott, Neil J. ; Olivares-Morales, Andrés ; Lavé, Thierry ; Rowland, Malcolm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a18cbdadbee7461cbdcdc79189e4c503c8b1c5197235e7ca3db0790fa28d8fbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Clinical Trials as Topic</topic><topic>Drug Delivery Systems - methods</topic><topic>Humans</topic><topic>Small Molecule Libraries - pharmacokinetics</topic><topic>Tissue Distribution - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Dennis A.</creatorcontrib><creatorcontrib>van Waterschoot, Robert A.B.</creatorcontrib><creatorcontrib>Parrott, Neil J.</creatorcontrib><creatorcontrib>Olivares-Morales, Andrés</creatorcontrib><creatorcontrib>Lavé, Thierry</creatorcontrib><creatorcontrib>Rowland, Malcolm</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Dennis A.</au><au>van Waterschoot, Robert A.B.</au><au>Parrott, Neil J.</au><au>Olivares-Morales, Andrés</au><au>Lavé, Thierry</au><au>Rowland, Malcolm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Importance of target-mediated drug disposition for small molecules</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2018-12</date><risdate>2018</risdate><volume>23</volume><issue>12</issue><spage>2023</spage><epage>2030</epage><pages>2023-2030</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•Target-mediated drug disposition for small molecules is not addressed systematically.•TMDD has a major influence on drug distribution and clearance.•TMDD results in unpredictable and non-linear pharmacokinetics.•TMDD confounds human microdosing approaches.
Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situation will generate pharmacokinetic (PK) profiles that deviate greatly from those normally expected, owing to target binding affecting drug distribution and clearance. Such target-mediated drug disposition (TMDD) effects on small molecules have received little attention and might only become apparent during clinical trials, with the potential for data misinterpretation. TMDD also confounds human microdosing approaches by providing therapeutically unrepresentative PK profiles. Being aware of these phenomena will improve the likelihood of successful drug discovery and development.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29928850</pmid><doi>10.1016/j.drudis.2018.06.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9959-0810</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-6446 |
ispartof | Drug discovery today, 2018-12, Vol.23 (12), p.2023-2030 |
issn | 1359-6446 1878-5832 |
language | eng |
recordid | cdi_proquest_miscellaneous_2058499901 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Clinical Trials as Topic Drug Delivery Systems - methods Humans Small Molecule Libraries - pharmacokinetics Tissue Distribution - physiology |
title | Importance of target-mediated drug disposition for small molecules |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T08%3A50%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Importance%20of%20target-mediated%20drug%20disposition%20for%20small%20molecules&rft.jtitle=Drug%20discovery%20today&rft.au=Smith,%20Dennis%20A.&rft.date=2018-12&rft.volume=23&rft.issue=12&rft.spage=2023&rft.epage=2030&rft.pages=2023-2030&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2018.06.010&rft_dat=%3Cproquest_cross%3E2058499901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2058499901&rft_id=info:pmid/29928850&rft_els_id=S1359644618300837&rfr_iscdi=true |